ORLANDO, Fla., Jan. 13, 2011 /PRNewswire/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, has announced that Robert B. Trussell, former CEO and founder of Tempur-Pedic, Inc., has recently formed a company to distribute genetically customized products developed by GeneLink. Mr. Trussell, through his new company, intends to market the product line utilizing techniques similar to those he used so successfully at Tempur-Pedic, including internet sales, short form TV and infomercials, newspapers, magazines, trade publications and radio. Mr. Trussell, who has brought back together a number of the former key staff members responsible for the early success of Tempur-Pedic, said, "We're especially excited to be teamed up with a company so similar to Tempur-Pedic, with unique technology with a point of difference that offers extraordinary value to consumers, a high end product line, and first mover status in a hot category." He added, "Numerous patents and patents pending by GeneLink will allow us to focus exclusively on developing the marketing of this remarkable product line. We're especially excited to see so many of the original team members coming together again on another venture of this magnitude. We are all really looking forward to the challenges and opportunities that lie ahead!" Bernard L. Kasten Jr., M.D. GeneLink's Executive Chairman and CEO added, "We are very excited to be partnering with Bobby Trussell and his team. Bobby has long been a supporter of both GeneLink and our direct selling subsidiary, GeneWize. Bobby's organization has most recently been instrumental in developing new Affiliate acquisition techniques with and for GeneWize. We anticipate these efforts will be increasingly fruitful as our working relationship expands. This new relationship provides us with a world class partner who has a proven track record in marketing scientifically advanced consumer products like our genetically-guided nutrition and skin care. Our agreement also provides GeneLink with some of the additional financial capital needed to help us expand R&D, product development, product validation, infrastructure and continued leadership in regulatory compliance and quality. As the pioneer in genetically-guided nutrition and skin care, GeneLink continues to focus on strengthening our leadership position and leading the growth in consumer genetics. Along with our two other distribution channels, our relationship with Bobby and his team should help expand both our top and bottom line growth." About GeneLink Biosciences, Inc.: GeneLink is a 16-year old leading biosciences company specializing in consumer genomics. GeneLink's patented technologies include proprietary DNA test assessments linked to personalized health, beauty and wellness applications and products. Its DNA assessments provide information that enables the customization of nutritional and skincare products designed and manufactured to fulfill each individual consumer's wellness needs. For more information visit www.genelinkbio.comAbout Robert B. Trussell, Jr.:Robert B. Trussell, Jr., 59, has served as a member of Tempur-Pedic International's Board of Directors or its predecessors since 1992, and has served as Vice Chairman of the Board of Directors since April 2006. Mr. Trussell served as Chief Executive Officer of Tempur-Pedic International or its predecessors from 1992 until May 2006. Tempur-Pedic International Inc. (NYSE: TPX) manufactures and distributes mattresses and pillows made from its proprietary TEMPUR® pressure-relieving material and is the worldwide leader in premium and specialty sleep. This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise. SOURCE GeneLink, Inc.